A company is preparing human trials of a DNA-based, universal influenza vaccine.
The first doses of H1N1 flu (swine flu) vaccine are due to be shipped to hospitals around the country in the next few weeks--seven months after the virus strain was first identified. These vaccine doses will use either inactivated or weakened live viruses to prompt immunity--an approach that can fail if any of the live viruses is strong enough to replicate, or if the inactivated viruses have been killed beyond all immune recognition.
& 
Compatiable 